Grant: Engage Grants Program
University of Victoria
$25,000.00
StressMarq biosciences - alpha synuclein oligomer antibody validation
EF 2017-18
Résumé
This project will allow StressMarq, a company that specializes in making antibodies, and Dr. Christie'slaboratory at the University of Victoria to investigate a novel alpha synuclein aggregate. This aggregate hasprion-like properties, and is able - when active - to catalyze the formation of Lewy Bodies in vivo fromendogenous alpha synuclein monomers found in the host environment. Lewy Bodies are a hallmark of LewyBody dementia, often described as being a subset of Parkinson's disease (approximately 25% of Parkinson'spatients have this pathology). The project will involve ""mapping"" the expression of the pathology and activityof the antibody using immunohistochemistry on rat or mouse brain slices harvested from animals with varyingcontrolled neurological backgrounds, something routinely done in the Christie laboratory. The ability to workwith cell culture would show if the antibody can neutralize the Lewy Body pathology when induced in thesecells, and if successful, the same could be carried out in rats.
Programme
Engage Grants Program
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
509804-2017
Name nom
Christie, Brian
Department département
Island Medical Program
Organization id
7
Institution établissement
University of Victoria
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2017
Competition year année de concours
2017
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1554
Committee name en
Pacific Internal Decision Committee
Committee name fr
Comité de décision interne pour le Pacifique
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
5305
Research subject group en
Molecular biology
Research subject group fr
Biologie moléculaire
Research subject en
Protein manipulation and expression
Research subject fr
Expression et recombinaison protéiques
Partie
1
Nb partie
1
Application title
StressMarq biosciences - alpha synuclein oligomer antibody validation
Keyword
NSERC
Application summary
This project will allow StressMarq, a company that specializes in making antibodies, and Dr. Christie'slaboratory at the University of Victoria to investigate a novel alpha synuclein aggregate. This aggregate hasprion-like properties, and is able - when active - to catalyze the formation of Lewy Bodies in vivo fromendogenous alpha synuclein monomers found in the host environment. Lewy Bodies are a hallmark of LewyBody dementia, often described as being a subset of Parkinson's disease (approximately 25% of Parkinson'spatients have this pathology). The project will involve ""mapping"" the expression of the pathology and activityof the antibody using immunohistochemistry on rat or mouse brain slices harvested from animals with varyingcontrolled neurological backgrounds, something routinely done in the Christie laboratory. The ability to workwith cell culture would show if the antibody can neutralize the Lewy Body pathology when induced in thesecells, and if successful, the same could be carried out in rats.